171 related articles for article (PubMed ID: 17519899)
1. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis.
Matakidou A; El Galta R; Rudd MF; Webb EL; Bridle H; Eisen T; Houlston RS
Br J Cancer; 2007 Jun; 96(12):1904-7. PubMed ID: 17519899
[TBL] [Abstract][Full Text] [Related]
2. Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: an analysis of survival in 619 female patients.
Matakidou A; El Galta R; Webb EL; Rudd MF; Bridle H; Eisen T; Houlston RS;
Lung Cancer; 2007 Aug; 57(2):207-12. PubMed ID: 17400332
[TBL] [Abstract][Full Text] [Related]
3. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.
Falvella FS; Frullanti E; Galvan A; Spinola M; Noci S; De Cecco L; Nosotti M; Santambrogio L; Incarbone M; Alloisio M; Calabrò E; Pastorino U; Skaug V; Haugen A; Taioli E; Dragani TA
Int J Cancer; 2009 Jun; 124(12):2880-5. PubMed ID: 19296538
[TBL] [Abstract][Full Text] [Related]
4. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
5. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients.
Spinola M; Leoni V; Pignatiello C; Conti B; Ravagnani F; Pastorino U; Dragani TA
J Clin Oncol; 2005 Oct; 23(29):7307-11. PubMed ID: 16061909
[TBL] [Abstract][Full Text] [Related]
6. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.
Ye Y; Shi Y; Zhou Y; Du C; Wang C; Zhan H; Zheng B; Cao X; Sun MH; Fu H
Ann Surg Oncol; 2010 Dec; 17(12):3354-61. PubMed ID: 20844967
[TBL] [Abstract][Full Text] [Related]
7. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor.
Frullanti E; Berking C; Harbeck N; Jézéquel P; Haugen A; Mawrin C; Parise O; Sasaki H; Tsuchiya N; Dragani TA
Eur J Cancer Prev; 2011 Jul; 20(4):340-7. PubMed ID: 21412156
[TBL] [Abstract][Full Text] [Related]
8. FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men.
Ho CK; Anwar S; Nanda J; Habib FK
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):94-6. PubMed ID: 19918264
[TBL] [Abstract][Full Text] [Related]
9. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
[TBL] [Abstract][Full Text] [Related]
10. [Bronchial cancer--development, diagnosis, therapy, prognosis].
Zöchbauer S; Krajnik G; Huber H
Wien Klin Wochenschr; 1994; 106(14):431-47. PubMed ID: 7941590
[TBL] [Abstract][Full Text] [Related]
11. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract][Full Text] [Related]
12. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma.
Tanuma J; Izumo T; Hirano M; Oyazato Y; Hori F; Umemura E; Shisa H; Hiai H; Kitano M
Oncol Rep; 2010 Mar; 23(3):739-44. PubMed ID: 20127014
[TBL] [Abstract][Full Text] [Related]
13. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
Ma Z; Tsuchiya N; Yuasa T; Inoue T; Kumazawa T; Narita S; Horikawa Y; Tsuruta H; Obara T; Saito M; Satoh S; Ogawa O; Habuchi T
Int J Cancer; 2008 Dec; 123(11):2574-9. PubMed ID: 18756523
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in apoptosis-related genes and survival of patients with early-stage non-small-cell lung cancer.
Lee EB; Jeon HS; Yoo SS; Choi YY; Kang HG; Cho S; Cha SI; Choi JE; Park TI; Lee BH; Park RW; Kim IS; Kang YM; Kim CH; Jheon S; Jung TH; Park JY
Ann Surg Oncol; 2010 Oct; 17(10):2608-18. PubMed ID: 20422457
[TBL] [Abstract][Full Text] [Related]
16. Survival of chemo-radiotherapy-treated and thermotherapy-treated patients with unresectable lung cancer.
Rizzo S
Oncol Rep; 1998; 5(3):667-71. PubMed ID: 9538173
[TBL] [Abstract][Full Text] [Related]
17. Lung cancer.
Giaccone G; Smit EF
Cancer Chemother Biol Response Modif; 2001; 19():485-534. PubMed ID: 11686030
[No Abstract] [Full Text] [Related]
18. The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer.
Kotsinas A; Evangelou K; Sideridou M; Kotzamanis G; Constantinides C; Zavras AI; Douglass CW; Papavassiliou AG; Gorgoulis VG
Cancer Lett; 2008 Feb; 259(2):177-85. PubMed ID: 18037232
[TBL] [Abstract][Full Text] [Related]
19. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.
da Costa Andrade VC; Parise O; Hors CP; de Melo Martins PC; Silva AP; Garicochea B
Exp Mol Pathol; 2007 Feb; 82(1):53-7. PubMed ID: 17084840
[TBL] [Abstract][Full Text] [Related]
20. [To be cured of lung cancer].
Depierre A; Jacoulet P; Westeel V; Falcoz PE
Bull Cancer; 2002 Apr; 89(4):351-6. PubMed ID: 12016035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
